Molecular Biology of Sars-Cov-2: Opportunities for Antivirus Drug Development
Haseltine William A.,Patarca Roberto
Synopsis "Molecular Biology of Sars-Cov-2: Opportunities for Antivirus Drug Development"
Offering a thorough, accessible overview of the basic science and clinical data regarding the virus that causes COVID-19, Molecular Biology of SARS-CoV-2 is an excellent resource for researchers, clinical scientists, physicians, and students. This volume offers in-depth, extended content that originated with Drs. Roberto Patarca's and William A. Haseltine's chapter in The COVID-19 Textbook, edited by Dr. Haseltine and Dr. Patarca. The greatly expanded material in this text provides a much-needed primer in this complex area. Reviews the basic science, clinical data and various perspectives on how SARS-CoV-2 infects cells, replicates, manipulates cellular machinery, evades host defenses, and is transmitted to other hosts Covers the origin and structure of SARS-CoV-2, followed by chapters based on the life cycle of the virus Provides a thorough review of what is known for each molecular component of the viral life cycle while incorporating information on pertinent prevention and therapeutic interventions About the Authors Roberto Patarca, MD, PhD Dr. Patarca is the Chief Medical Officer at ACCESS Health International and a former pharmaceutical and medical device company executive and faculty at Harvard Medical School and the University of Miami. His research has focused on the AIDS virus, microbial replication regulation, adoptive cellular immunotherapy, drug resistance testing, cardiovascular interventions, and chronic fatigue syndrome. He served on Advisory Committees to two U.S. Secretaries of Health and Human Services, was elected to the Academy of Sciences of Latin America; worked with the World Health Organization on standardization of cytokine level measurements, and has been published widely. William A. Haseltine, PhD In Dr. Haseltine's career at the forefront of medical research and application, he has educated a generation of doctors at Harvard Medical School, designed the strategy to develop the first treatment for HIV/AIDS, is well-known for his groundbreaking work on cancer, and led the team that pioneered the development of new drugs based on information from the human genome. He is the author of more than two hundred peer-reviewed manuscripts and fifteen books. As Chair and CEO of ACCESS Health International, Dr. Haseltine is dedicated to ensuring that advances in medical technology translate to improved health outcomes worldwide.
